AI Unites Global Data in Landmark Prostate Cancer Research Initiative

NEW YORK, NY – February 18, 2026 – In a significant move to accelerate the fight against prostate cancer, healthtech leader Flatiron Health has launched a first-of-its-kind global data platform, leveraging artificial intelligence to unify real-world patient records from across the United States, United Kingdom, and Germany. The initiative promises to break down long-standing barriers in international cancer research, offering unprecedented insights into a disease that affects nearly 1.5 million people annually.

The AI Engine Breaking Down Borders

At the heart of the announcement is the expansion of Flatiron's Global Evidence Platform to include new "Panoramic" datasets for prostate cancer. This is not merely about adding more data; it's about creating a cohesive, queryable resource from disparate and historically siloed healthcare systems. The platform now encompasses the anonymized records of nearly 400,000 prostate cancer patients.

The key technological innovation lies in the company's proprietary AI and large language models (LLMs). A significant portion of critical patient information—such as nuanced clinical observations, rationale for treatment changes, and details of disease progression—is often buried within unstructured, free-text physician notes in Electronic Health Records (EHRs). Flatiron's AI is engineered to read, interpret, and extract this vital information at a massive scale. This includes granular details crucial for modern oncology, such as Prostate-Specific Membrane Antigen (PSMA) PET scan results, longitudinal prostate-specific antigen (PSA) values, and the status of 19 different Homologous Recombination Repair (HRR) genes.

This raw, multi-format data is then standardized into a "common data model." This process harmonizes information across different languages, measurement units, and clinical practices, effectively creating a single, interoperable dataset. For researchers, this means they can now analyze patient journeys and treatment outcomes across three major international markets as if they were studying a single population, a feat previously considered infeasible. To ensure the reliability of this automated process, the company employs a rigorous quality control framework known as VALID, which benchmarks the AI's accuracy against that of expert human data abstractors.

Closing the Evidence Gap in Patient Care

The clinical implications of this unified data are profound. The treatment landscape for prostate cancer is evolving at a breakneck pace, with new diagnostics and therapies constantly emerging. However, significant "evidence gaps" remain, as treatment patterns, access to novel therapies, and patient outcomes can vary dramatically from one country to another.

"The field of prostate cancer is evolving at a rapid pace, changing how care is sequenced from early-stage disease through metastatic CRPC and improving outcomes for patients," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health, in the company's announcement. "Yet critical evidence gaps remain, as we see significant regional variation in how novel therapies are used, and in how uneven access to advanced diagnostics differentially influences treatment decisions."

By providing a panoramic view of real-world practices, the new datasets allow life science companies and clinical researchers to address these gaps directly. They can now investigate how a new drug performs not just in a controlled clinical trial, but in the messier, more complex reality of routine clinical care across different healthcare systems. This can accelerate drug development timelines and help regulators and payers make more informed decisions, ultimately broadening patient access to the next generation of precision medicine. The prostate cancer data also complements Flatiron's existing datasets in genitourinary cancers, including a comprehensive bladder cancer offering, creating a powerful resource for the field.

A Strategic Play in the Race for Oncology Intelligence

This launch is also a calculated strategic move in the rapidly growing market for real-world evidence (RWE). The global RWE solutions market is projected to surpass $6 billion by 2033, with oncology being the largest and most valuable segment. By launching the first and only global dataset for prostate cancer, Flatiron is solidifying its position as a dominant force in this space.

"Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence," stated Kate Estep, Chief Product Officer at Flatiron Health. This ambition pits the company against other major players in the health data industry, such as IQVIA, which also has a significant presence in European oncology data. However, Flatiron's unique selling proposition lies in its deep AI-driven integration of unstructured data and its foundation in oncology-specific EHR systems, which provides a level of clinical depth that is difficult to replicate.

The company, an independent affiliate of the Roche Group, has signaled that this is just the beginning. The prostate cancer launch is the first in a planned series of global expansions, with longitudinal datasets for breast cancer and non-small cell lung cancer (NSCLC) slated for 2027. This long-term vision underscores a broader industry trend: the future of drug development and cancer care will be increasingly shaped by insights derived from vast, interconnected, and intelligently curated real-world data.

The Bedrock of Trust: Data Privacy and Governance

Aggregating sensitive health information from multiple continents raises immediate and critical questions about data privacy and security. Flatiron's ability to operate globally hinges on a robust governance framework that complies with a complex web of international regulations, including Europe's stringent GDPR and the U.S.'s HIPAA.

The company's model relies on multilayered safeguards. In the UK, for instance, Flatiron partners directly with NHS hospitals, which provide patients with the opportunity to opt-out of having their data used for research. Before any data is analyzed, it undergoes a rigorous process of de-identification and anonymization, where direct patient identifiers are removed and replaced with pseudonyms. This anonymized data is then made available to researchers only within a secure, access-controlled Trusted Research Environment (TRE).

This meticulous approach, which has received approval from regulatory bodies like the UK's Health Research Authority (HRA), is designed to protect patient confidentiality while unlocking the immense research potential of the data. By building this foundation of trust with patients, providers, and regulators, the company is creating a sustainable model for the future of global health research, transforming individual patient experiences into powerful, decision-shaping insights that could redefine cancer care for years to come.